Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 2000, p. 925-931, Vol. 7, No. 6
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Clarithromycin Attenuates Mastectomy-Induced Acute
Inflammatory Response
Louis W. C.
Chow,1
Kwok-Yung
Yuen,2,*
Patrick C. Y.
Woo,2 and
William I.
Wei1
Department of Surgery1
and Department of Microbiology,2 The
University of Hong Kong, Queen Mary Hospital, Hong Kong
Received 11 February 2000/Returned for modification 30 May
2000/Accepted 14 August 2000
 |
ABSTRACT |
Based on the observation that administration of clarithromycin led
to an attenuation of the inflammatory response induced by surgical
trauma in a guinea pig model, we investigated the potential beneficial
effects of clarithromycin on the local and systemic inflammatory
response in patients undergoing mastectomy in an open-label prospective
study. During a 16-month period, 54 patients who underwent mastectomy
were randomly divided into two groups. In one group, the patients
received oral clarithromycin at a dose of 500 mg twice a day, from the
day before to 3 days after mastectomy. There was no significant
difference in the incidence of antibiotic prophylaxis-related
toxicities or postoperative infections between the patients who
received clarithromycin and those who did not. Clarithromycin treatment
was significantly associated with an attenuation of febrile response,
tachycardia, tachypnea, and an increase in monocyte counts
(P, <0.0001, <0.01, <0.05, and <0.01, respectively).
Clarithromycin also reduced the intensity and duration of postoperative
pain (P, <0.05 and <0.005, respectively) and increased
the range of motion of the involved shoulder (P < 0.05 for abduction and flexion). We conclude that clarithromycin
effectively modulates the acute inflammatory response associated with
mastectomy and produces a better clinical outcome.
 |
INTRODUCTION |
Surgical operations induce major
physiological and immunological changes. These changes are activated by
various stimuli, such as nociceptive stimulation, tissue injury, tissue
ischemia, reperfusion, and hemodynamic disturbances. The clinical
response is the result of complex changes, which include dysregulation of T-cell function, changes in the balance of cytokines and
counterregulatory hormones, and increased hepatic synthesis of
acute-phase reactants. In most patients, the systemic changes are
minimal and self-limiting. However, in patients with complicated
surgery or major trauma, the response becomes extensive and prolonged,
resulting in systemic inflammatory response syndrome (SIRS), which is
characterized by increased or suppressed body temperature,
increased heart rate, hyperventilation, and an abnormal
peripheral leukocyte count (2). Although an
inflammatory response is an inevitable and essential part of the repair
process and a natural defensive reaction to prevent infections
associated with trauma, such undesirable fallout from surgical
treatment is associated with significant morbidity and even mortality.
The macrolide group of antibiotics is associated with in vitro and in
vivo immunomodulating activities (18, 31-33). Erythromycin, one of the macrolides, has been used extensively for antimicrobial prophylaxis in colorectal surgery (22). Recently, it has
also been shown that clarithromycin attenuates the inflammatory
response induced by surgical trauma in a guinea pig model
(32).
Mastectomy is a suitable surgical procedure for the study of the acute
inflammatory response to surgery because the extensive dissection
causes significant tissue damage and bacterial contamination of the
surgical site is uncommon. In this study, we report the clinical
profile of the local and systemic inflammatory responses due to
mastectomy and the effects of clarithromycin on the mastectomy-induced acute inflammatory response in an open-label, prospective,
randomized-control trial.
 |
MATERIALS AND METHODS |
Preoperative protocol.
Approval from the local ethics
committee was obtained for this trial. Patients were recruited between
February 1997 and May 1998. The diagnosis of breast cancer was
confirmed by mammographic examinations and cytological examinations of
fine-needle aspirates before the operation. Patients who were pregnant
and those with diabetes mellitus, cirrhosis of the liver, chronic renal
failure, myasthenia gravis, a bleeding tendency, history of allergy to macrolides, antibiotic treatment within 2 weeks of the study, or
long-term immunosuppression were excluded from the study. If there were
no reasons for exclusion, the nature and purpose of the trial were
explained to the patients and informed consent was obtained for
inclusion in the trial. Fifty-six patients with breast cancer were
recruited for the randomized trial. Two patients in the control group
dropped out due to refusal of venipuncture. One patient from each group
underwent additional transrectus abdominal myocutaneous (TRAM) flap
surgery for breast reconstruction.
Blood was drawn from patients the day before the operation for a
preanesthetic workup that included complete blood counts, differential
white cell counts, renal and liver function tests, coagulation
profiles, erythrocyte sedimentation rate (ESR), and C-reactive protein
(CRP) level. Levels of interleukin-6 (IL-6) and tumor necrosis factor
alpha (TNF-
) in serum were also determined.
Randomization.
Consecutive patients (except those excluded)
were enrolled and randomized into two groups by computer. Patients in
the study group were given oral clarithromycin (500 mg twice a day)
from the day before to 3 days after the operation. Patients in the control group did not receive any clarithromycin. All surgeons and
medical staff responsible for assessing the outcome were unaware of the
randomization results because separate prescription sheets were given
for the clarithromycin prescription.
Anesthesia.
All patients underwent standard general
anesthesia. They were not given any premedication except for the single
morning dose of clarithromycin. Induction was done with thiopenal,
fentanyl, and vecuronium, and maintenance was achieved with nitrous
oxide and isoflurane. Fentanyl and vecuronium were given as required.
Surgical procedures.
The operation involved the total
removal of the breast and axillary dissection up to the level II lymph
nodal station. The raising of the flaps and tissue dissection during
mastectomy were performed by electric cautery. Closed-suction drains
were placed at the chest and axilla after the mastectomy and a deep
culture swab was taken from the surgical wound before closure. The
wound was closed by interrupted subcuticular sutures.
Two patients underwent additional TRAM flap reconstruction. This
involved the raising by electric cautery of extensive abdominal skin
and subcutaneous tissue from the underlying muscle and fascia. The
rectus muscles and the overlying flap were harvested and placed at the
mastectomy site. The defect in the abdominal wall was closed by primary closure.
Patients were closely monitored during the operation. Blood loss,
operative time, administration of anesthetic drugs, and intravenous
fluid were recorded. A deep wound swab for bacterial culture was taken
at the operation site. The area of dissection for mastectomy and TRAM
flap reconstruction was measured by placing the specimen or the
harvested flap on a piece of paper and marking out the surface area.
Postoperative management.
The patients were monitored at 4-h
intervals after the operation for elevation of temperature, respiratory
rate, and heart rate. Postoperative pain was treated with oral
acetaminophen and intravenous propoxyphene hydrochloride, given on an
as-needed basis every 4 h. The intensity of pain was charted every
4 h and whenever analgesics were given, using a visual log scale
from 0 to a maximum of 10 (1). The intravenous-fluid
requirement and the urine output for the first 48 h were
monitored. The amount of drain fluid was charted daily until the drains
were removed. The wound was inspected daily and any development of flap
necrosis, infection (cellulitis with a purulent discharge), or blister
formation was charted. Blood samples were taken at the peak of the
febrile episodes and cultured to monitor for any possible transient
bacteremia. Each set of blood cultures consisted of an aerobic bottle
with resin and an anaerobic bottle, and the BACTEC 9240 blood culture system (Becton Dickinson, Gaithersburg, Md.) was used. The range of
movement of the shoulder on the corresponding side of the surgery was
charted on postoperative day 5 by an experienced physiotherapist who
was not aware of the randomization results.
Blood was drawn immediately after the operation in the recovery room
and on postoperative days 1, 2, and 5. Except for the renal and liver
function tests, the samples were tested for the parameters listed in
the preoperative protocol. Drain fluid was also collected on
postoperative days 1, 2, and 5. The drain fluid was sent for bacterial
culture and tested for total cell and differential counts. Biochemical
assays of serum and drain fluid were also performed to analyze the
levels of CRP, IL-6, and TNF-
.
Measurement of IL-6 and TNF-
by enzyme-linked immunosorbent
assays.
Commercial kits (Boehringer GmbH, Mannheim, Germany) were
used for all enzyme-linked immunosorbent assays. Serum samples were centrifuged at high speed to remove turbidity and particles.
Immunoreagent solution was prepared by adding 50 µl of
peroxidase-conjugated detection antibody to 0.9 ml of incubation
buffer, and 50 µl of biotin antibody was added after mixing. Twenty
microliters of each supernatant was added into the microtiter plate
provided, and 200 µl of immunoreagent was pipetted into all wells
containing the test samples. The microtiter plate was then covered
tightly with adhesive foil and incubated for 2 h at room
temperature on a shaker at 250 rpm. The incubation buffer was removed
by tapping and the wells were rinsed three times with washing buffer.
The washing solution was removed and 200 µl of substrate solution was
added to the wells. The microtiter plate was covered again with the
adhesive foil and incubated in the same manner for another 20 to 30 min
at room temperature. Fifty microliters of stop solution was added to
each well, and after incubation for 1 min the plate was read by using a
spectrophotometer at 450 nm (reference wavelength, 690 nm).
Statistical analysis.
Parameters were compared using SPSS
software, release 6.0 (SPSS Inc., Chicago, Ill.). Interval changes in
the physiological and hematological parameters, acute-phase proteins,
and cytokines were analyzed with reference to preoperative values.
One-way analysis-of-variance tests were used to compare means in each
group over the time period studied. Fisher's exact test or the
chi-square test was used to compare the number of events between
groups. Bivariate correlation was performed for univariate analysis.
All values are means and standard errors of the means (SEM), unless
otherwise stated. A P value of <0.05 was considered
statistically significant.
 |
RESULTS |
Patients.
There were no significant differences between the
two groups in terms of age, area of dissection, blood loss, operation
time, and the amount of parenteral fluid administered during the
perioperative period (Table 1). The
culture swabs taken during the operation were negative for bacterial
growth for all 54 patients.
Acute inflammatory response after mastectomy.
The parameters
reflecting a systemic inflammatory response were analyzed in the
control group. There was a progressive elevation of temperature, heart
rate, and respiratory rate above preoperative levels (Fig.
1) until postoperative day 5. Mastectomy
produced significant changes in temperature (P < 0.0001) and heart rate (P < 0.001). The changes
in respiratory rate did not reach statistical significance.
The hematological parameters after mastectomy are shown in Fig.
2. There was a drop in hemoglobin and the
interval changes were statistically significant (P < 0.0001). The changes in white blood cell and platelet counts, on
the other hand, were more marked. There was an elevation of white blood
cell counts almost immediately after the operation. This returned to
the preoperative level on day 5. The interval changes were
statistically significant (P < 0.0001). The platelet
counts showed a different time trend. There was an immediate drop after
mastectomy and this persisted until 48 h after surgery. However,
the counts returned to the preoperative level on postoperative day 5. The interval changes were not statistically significant. The elevation
of neutrophil counts was greatest on the day of the operation and
monocyte counts reached a peak 48 h after the operation (Fig.
3). The interval changes in monocyte and
neutrophil counts were statistically significant (P < 0.0001 for both parameters). On the other hand, there was progressive lymphopenia after the operation; the percentage changes increased on the day of the operation but dropped below the basal level
from postoperative day 1 to 5.
The other parameters reflecting acute inflammatory reactions are shown
in Fig. 4. The interval changes in CRP
and ESR were statistically significant (P, <0.005 and
<0.0001). Statistical significance was not reached for changes in
levels of IL-6 and TNF-
.
Effects of clarithromycin on the mastectomy-induced acute
inflammatory response.
The results of the comparison between the
clarithromycin and control groups for the mean interval changes in
physiological, hematological, and other laboratory parameters measured
for the acute inflammatory response are summarized in Table
2. The differences between the two groups
were statistically significant for changes in temperature, heart rate,
respiratory rate, and monocyte count. The differences in changes in
neutrophil count and ESR did not reach statistical significance.
When the total amount of drain fluid was analyzed, the mean amount
(±SEM) of drain fluid for the control group was 926 (±88.1) ml,
whereas that for the clarithromycin group was 1,052 (±145.0) ml. There
was no statistically significant difference between the two groups. The
durations of drainage output were 7.8 (±0.53) days and 7.9 (±0.54)
days for the control and clarithromycin groups, and again there was no
statistically significant difference. The total white blood cell count
and differential counts, as well as the levels of CRP, IL-6, and
TNF-
in the drain fluid, showed no statistically significant
difference between the two groups.
The intensity of pain from mastectomy was higher for the control group
of patients. The mean score was 4.2 (±0.43) for the control group, and
the corresponding value for the clarithromycin group was 3.2 (±0.35).
The difference was statistically significant (P < 0.05). The duration of pain was also longer for the control group.
The mean durations for the control and clarithromycin groups were 3.98 (±0.34) days and 2.63 (±0.31) days, respectively. The difference was
statistically significant (P < 0.005). The patients of
the control group consumed more analgesics for relief of pain. The mean
frequencies of analgesic consumption for the control and clarithromycin
groups were 2.77 (±0.41) and 1.35 (±0.24) times, respectively, and
the difference was statistically significant (P < 0.005).
Postoperative functional status in terms of range of shoulder abduction
and flexion was better for the clarithromycin group. The mean range of
abduction for the control group was 66.2° (±4.2°), whereas the
mean value for the clarithromycin group was 80.0° (±5.2°)
(P < 0.05). The corresponding values for the range of flexion were 76.5° (±4.2°) and 91.2° (±4.7°) for the
respective groups (P < 0.05).
No patients developed a wound infection. Wound flap necrosis for both
groups was minor and limited to the wound edge. Five and two patients
of the control and clarithromycin groups developed flap necrosis, respectively.
 |
DISCUSSION |
Surgery induces both inflammation and immunosuppression, resulting
in the development of local and systemic inflammatory responses (8). These responses usually abate spontaneously. However, when they are excessive, physiological homeostasis is upset and when
challenged by additional insults, deleterious effects, such as severe
SIRS and multiorgan dysfunction, may occur.
Clinical researchers have been looking for ways to modulate the
physiological responses after surgery. Anesthetic agents have effects
on the immune system (12, 19, 23). The cell number and
activity of natural killer cells are diminished during induction and
there is a change in the balance of pro- and anti-inflammatory cytokines. Corticosteroids are powerful drugs for inflammatory conditions, and parenteral administration of betamethasone, for example, can significantly reduce postoperative swelling and pain (11, 28). Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in reducing postoperative pain, but their modulating effect
on the systemic inflammatory response after surgery is not
satisfactory. Epidural analgesia in combination with systemic indomethacin markedly reduces postoperative pain (27).
However, the elevation of plasma cortisol, acute-phase proteins, and
leukocyte and differential counts, which are changes typical of the
acute-phase response, are only minimally modulated. Moreover, when the
effect of an NSAID was compared with that of glucocorticoid, the
steroid was found to have a greater effect than the NSAID on
suppression of postoperative inflammation (30). Furthermore,
when the combined effect of prednisolone, epidural analgesia, and
systemic indomethacin was studied, the leukocytic reaction and
acute-phase response were unmodified (7, 10). Another
approach utilizes synthetic analogues of thymic hormones, such as
thymopentin, to combat the immunosuppression associated with major
surgery (3). It has been shown that thymopentin, in
combination with indomethacin, can adequately preserve and/or restore
intact macrophage and T-cell interaction and thus appears to be a
feasible approach to maintain normal host defense activity in patients
undergoing major surgery (14). In addition, thymopentin has
been shown to reduce mortality in experimental thermal injury
(5). The improvement in host survival is related to the
reduction in levels of IL-4 and increased production of IL-2.
With the advent of laparoscopic technology, clinical studies have shown
that the reduction in the extent of surgical dissection by laparoscopic
surgery reduces nociceptive stimulation and consequently the
neuroendocrine response. This is evident by the reduction in
postoperative pain and early return to normal function. The granulocyte
count and IL-6 level were lower in patients undergoing laparoscopic
surgery (16, 17, 20), and the immunocompetence measured by
phytohemagglutinin responsiveness was also stronger for the
laparoscopic group (17). Laparoscopic surgery is associated with a significant decrease in monocyte and neutrophil release of
O2
, TNF-
, chemotaxis, and white blood cell
count (29). However, CD4/CD8 ratios were still decreased
after laparoscopic surgery but reverted back to normal 1 week later
(15). When laparoscopic surgery has been compared with
minilaparotomy, earlier studies reported that laparoscopic surgery was
superior in reducing hospital stay and postoperative dysfunction as
well as leading to a quicker return to normal activities. However,
subsequent reports did not show any improvement in postoperative
recovery and respiratory impairment or any reduction in neuroendocrine
response and cortisol production (4, 24, 34). When
laparoscopic surgery involving a larger extent of surgical dissection,
such as laparoscopic adrenalectomy, was compared with open surgery,
white blood cell count and CRP level, two parameters that reflect acute
inflammation, did not differ significantly between groups
(6). Therefore, laparoscopic surgery is not the complete
answer for reducing the harmful effects caused by surgical trauma.
Studies comparing mastectomy with other major surgeries, such as
esophagectomy and pulmonary lobectomy, demonstrated that mastectomy
could induce higher neutrophil, adrenocorticotropin, and cortisol
levels (9). In the present study, we also found slight
lymphopenia after mastectomy, in addition to the elevation of
neutrophil and monocyte counts. Therefore, mastectomy provides a good
opportunity for the study of immunomodulation after surgical trauma.
The amount of energy applied to the whole operative field is adequate
to produce a significant local inflammatory response at the operative
site in all patients and SIRS in a certain proportion of patients.
Twenty-four of 26 patients in the control group (92.3%) developed one
or more features of an inflammatory response after mastectomy. Nine
patients (34.6%) met the criteria for SIRS (2).
An effective antibiotic, besides having an antimicrobial effect, may
also be a potent immunomodulator to combat the alteration of the immune
system. The modulation of the immune system by antibiotics was first
observed by Metchnikoff and Helmholz (cited in reference 13). They reported the contradictory results of
enhancement and depression of phagocyte functions by quinine.
Antibiotics of the macrolide group, such as azithromycin, erythromycin,
and roxithromycin, have also been reported to have immunomodulating effects (18, 21, 25).
In a previous study on the effects of clarithromycin on surgical trauma
in an animal model, the neutrophil and monocyte counts of the
clarithromycin-treated group were significantly lower than those of the
control group (32). The platelet counts were also lower for
the clarithromycin group. In addition, there was a trend towards a
milder elevation of temperature and respiratory rate in the group of
animals pretreated with clarithromycin. Based on these observations, it
was concluded that clarithromycin suppresses both the local and
systemic inflammatory responses after surgical trauma.
In the present study, we found that there was a marked reduction in the
acute-phase response in the clarithromycin group. The important
parameters, such as temperature, heart rate, and respiratory rate,
showed significantly smaller changes in the clarithromycin group than
in the control group. When the parameters were analyzed on interval
scales, there was a greater reduction in the elevation of temperature
for the clarithromycin group. The changes in the heart and respiratory
rates were also significantly less than in the control group. Although
the changes in white cell counts did not reach statistical
significance, the increase in monocyte count in the clarithromycin
group was significantly less than that in the control group.
The clinical effects of clarithromycin at the surgical site were
assessed. The intensity as well as the duration of pain was lower in
the clarithromycin group than in the control group. The frequency of
analgesic use was also lower. The range of movement was significantly
greater than in the control group. Moreover, the odds ratios for wound
infection and necrosis were lower for patients treated with
clarithromycin. These parameters reflect that this macrolide has a
considerable "cleansing" effect at the operative site, leading to a
much weaker local inflammatory response and a much better clinical
outcome. In addition to the immunomodulatory effects of clarithromycin
on surgical trauma, this drug has also been reported to be a potent
inhibitor of tumor-induced angiogenesis in a mouse cancer model
(35). A clinical study also demonstrated that the drug
prolonged survival of patients with unresectable non-small-cell lung
cancer by increasing the bioactivity of IL-12 and natural killer cell
activity (26). One important limitation of using
clarithromycin for immunomodulatory prophylaxis in surgical trauma is
the possibility of inducing antimicrobial resistance. This could be
overcome by developing clarithromycin analogues which do not have
antimicrobial activities. In the meantime, further studies should be
conducted to assess if a single dose or 48-h doses of clarithromycin
would also be effective.
These observations reflect that clarithromycin has the capacity to
modulate the inflammatory response resulting from surgical trauma.
Although it was not apparent statistically that the modulation was
mediated through changes in IL-6, CRP, or TNF-
, the mean values for
these variables in the clarithromycin group were lower than in the
control group. Although the mechanism of action of clarithromycin
remains to be elucidated, it is likely that the drug acts on the
function and number of monocytes and macrophages, in a manner similar
to that of erythromycin. Of the leukocyte populations studied, we found
that there is a significant modulation by clarithromycin of the
increase in monocytes. The lymphopenia associated with surgical
operations was not nullified and the increase in neutrophils was not
reduced. The drug may not act on T cells directly, but when the
antigen-presenting capacity of monocytes is affected, T-cell function
may also be altered. The other possible mode of action could be related
to the augmentation of the capacity of phagocytosis by macrophages to
clean up the inflammatory debris from surgical operations. The
phagocytic augmentation is strong enough locally to reduce the
intensity of pain and shorten its duration. These actions enable the
drug to attenuate the development of SIRS. In conclusion, this
randomized-control, open-label, prospective study provided sufficient
evidence of macrolide modulation of surgical-trauma-related
inflammation. Further placebo-controlled trials with larger numbers of
patients and different operative procedures should be conducted to
ascertain the beneficial effects of immunomodulation in patients with
surgical trauma.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Phone: (852) 28553214. Fax: (852) 28551241. E-mail:
microgen{at}hkucc.hku.hk.
 |
REFERENCES |
| 1.
|
Ad Hoc Committee on Cancer Pain of the American Society of Clinical Oncology.
1992.
Cancer pain assessment and treatment curriculum guidelines.
J. Clin. Oncol.
10:1976-1982[Abstract].
|
| 2.
|
Bone, R. C.,
R. A. Balk,
F. B. Cerra,
R. P. Dellinger,
A. M. Fein,
W. A. Knaus,
R. M. Schein, and W. J. Sibbald.
1992.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.
Chest
101:1644-1655[Abstract/Free Full Text].
|
| 3.
|
Braga, M.,
L. Gianotti,
O. Gentilini,
C. Fortis,
G. Consogno, and V. DiCarlo.
1996.
Thymopentin modulates Th1 and Th2 cytokine response and host survival in experimental injury.
J. Surg. Res.
62:197-200[CrossRef][Medline].
|
| 4.
|
Carlone, N. A.,
A. M. Cuffini,
V. Tullio, and D. Sassella.
1989.
Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 2. Chemotaxis and phagocytosis of 3H-Staphylococcus aureus by human macrophages.
Microbios
58:17-25[Medline].
|
| 5.
|
Cho, J. M.,
A. LaPorta,
J. R. Clark,
M. J. Schofield,
S. L. Hammond, and P. L. Mallory, 2nd.
1994.
Response of serum cytokines in patients undergoing laparoscopic cholecystectomy.
Surg. Endosc.
8:1380-1383[Medline].
|
| 6.
|
Cuffini, A. M.,
N. A. Carlone,
V. Tullio, and M. Borsotto.
1989.
Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 3. Killing of intracellular Staphylococcus aureus by human macrophages.
Microbios
58:27-33[Medline].
|
| 7.
|
Faist, E.,
A. Markewitz,
D. Fuchs,
S. Lang,
S. Zarius,
F. W. Schildberg,
H. Wachter, and B. Reichart.
1991.
Immunomodulatory therapy with thymopentin and indomethacin. Successful restoration of interleukin-2 synthesis in patients undergoing major surgery.
Ann. Surg.
214:264-273[Medline].
|
| 8.
|
Faist, E.,
E. Faist, and C. Kim.
1998.
Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis.
New Horiz.
2(Suppl.):S97-S102.
|
| 9.
|
Fujii, T.,
J. Kadota,
K. Kawakami,
K. Iida,
R. Shirai,
M. Kaseda,
S. Kawamoto, and S. Kohno.
1995.
Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection.
Thorax
50:1246-1252[Abstract].
|
| 10.
|
Goldstein, G., and T. Audhya.
1985.
Thymopoietin to thymopentin: experimental studies.
Surv. Immunol. Res.
4:1-10.
|
| 11.
|
Higgs, G. A.,
S. Moncada, and J. R. Vane.
1979.
The role of arachidonic acid metabolites in inflammation, p. 419-430.
In
G. Weissmann, B. Samuelsson, and R. Paoletti (ed.), Advances in inflammatory research, vol. 1. Raven Press, New York, N.Y.
|
| 12.
|
Hjortso, N. C.,
P. Neumann,
F. Frosig,
T. Andersen,
A. Lindhard,
E. Rogon, and H. Kehlet.
1985.
A controlled study on the effect of epidural analgesia with local anaesthetics and morphine on morbidity after abdominal surgery.
Acta Anaesthesiol. Scand.
29:790-796[Medline].
|
| 13.
|
Keicho, N.,
S. Kudoh,
H. Yotsumoto, and S. Akagawa.
1994.
Erythromycin promotes monocyte to macrophage differentiation.
J. Antibiot.
47:80-89[Medline].
|
| 14.
|
Kloosterman, T.,
B. M. von-Blomberg,
P. Borgstein,
M. A. Cuesta,
R. J. Scheper, and S. Meijer.
1994.
Unimpaired immune functions after laparoscopic cholecystectomy.
Surgery
115:424-428[Medline].
|
| 15.
|
Kollmorgen, C. F.,
G. B. Thompson, and C. S. Grant.
1998.
Laparoscopic versus open posterior adrenalectomy: comparison of acute-phase response and wound healing in the cushingoid porcine model.
World J. Surg.
22:613-620[CrossRef][Medline].
|
| 16.
|
Majeed, A. W.,
G. Troy,
J. P. Nicholl,
M. W. R. Reed,
C. J. Stoddard, and A. G. Johnson.
1996.
Randomized, prospective, single-blind comparison of laparoscopic versus small-incision cholecystectomy.
Lancet
347:989-994[CrossRef][Medline].
|
| 17.
|
Maruszynski, M., and Z. Pojda.
1995.
Interleukin 6 (IL-6) levels in the monitoring of surgical trauma. A comparison of serum IL-6 concentrations in patients treated by cholecystectomy via laparotomy or laparoscopy.
Surg. Endosc.
9:882-885[Medline].
|
| 18.
|
Matsuoka, N.,
K. Eguchi,
A. Kawakami,
M. Tsuboi,
Y. Kawabe,
T. Aoyagi, and S. Nagataki.
1996.
Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells.
Clin. Exp. Immunol.
104:501-508[CrossRef][Medline].
|
| 19.
|
McBride, W. T.,
M. A. Armstrong, and S. J. McBride.
1996.
Immunomodulation: an important concept in modern anesthesia.
Anesthesia
51:465-473[Medline].
|
| 20.
|
McMahon, A. J.,
I. T. Russell,
J. N. Baxter,
S. Ross,
J. R. Anderson,
C. G. Morran,
G. Sunderland,
D. Galloway,
G. Ramsay, and P. J. O'Dwyer.
1994.
Laparoscopic versus minilaparotomy cholecystectomy: a randomized trial.
Lancet
343:135-138[CrossRef][Medline].
|
| 21.
|
Nagai, H.,
H. Shishido,
R. Yoneda,
E. Yamaguchi,
A. Tamura, and A. Kurashima.
1991.
Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis.
Respiration
58:145-149[Medline].
|
| 22.
|
Nichols, R. L.,
J. W. Smith,
R. Y. Garcia,
R. S. Waterman, and W. C. Holmes.
1997.
Current practices of preoperative bowel preparation among North American colorectal surgeons.
Clin. Infect. Dis.
24:609-619[Medline].
|
| 23.
|
Norman, J. G., and G. W. Fink.
1997.
The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial.
Am. Surg.
63:75-80[Medline].
|
| 24.
|
Panteix, G.,
B. Guillaumond,
R. Harf,
A. Desbos,
V. Sapin,
M. Leclercq, and M. Perrin-Fayolle.
1993.
In-vitro concentration of azithromycin in human phagocytic cells.
J. Antimicrob. Chemother.
31(Suppl. E):1-4[Free Full Text].
|
| 25.
|
Roche, Y.,
M. A. Gougerot-Pocidalo,
A. Fay,
N. Forest, and J. J. Pocidalo.
1986.
Macrolides and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation.
J. Antimicrob. Chemother.
17:195-203[Abstract/Free Full Text].
|
| 26.
|
Sakamoto, M.,
K. Mikasa,
K. Hamada,
M. Konishi,
K. Maeda,
E. Yoshimoto,
K. Ueda,
T. Majima,
M. Sawaki,
E. Kita, and N. Narita.
1998.
Effect of clarithromycin treatment on natural killer cell activity in patients with advanced non-small cell lung cancer.
Gan To Kagaku Ryoho
25:2259-2266[Medline].
|
| 27.
|
Schulze, S.,
O. Roikjaer,
L. Hasselstrom,
N. H. Jensen, and H. Kehlet.
1988.
Epidural bupivacaine and morphine plus systemic indomethacin eliminates pain but not systemic response and convalescence after cholecystectomy.
Surgery
103:321-327[Medline].
|
| 28.
|
Skjelbred, P., and P. Lokken.
1982.
Post-operative pain and inflammatory reaction reduced by injection of a corticosteroid a controlled trial in bilateral oral surgery.
Eur. J. Clin. Pharmacol.
21:391-396[CrossRef][Medline].
|
| 29.
|
Squirrell, D. M.,
A. W. Majeed,
G. Troy,
J. E. Peacock,
J. P. Nicholl, and A. G. Johnson.
1998.
A randomized, prospective, blinded comparison of postoperative pain, metabolic response, and perceived health after laparoscopic and small incision cholecystectomy.
Surgery
123:485-495[CrossRef][Medline].
|
| 30.
|
Troullos, E. S.,
K. M. Hargreaves,
D. P. Butler, and R. A. Dionne.
1990.
Comparison of nonsteroidal anti-inflammatory drugs, ibuprofen and fluprofen, with methylprednisolone and placebo for acute pain, swelling, and trismus.
J. Oral Maxillofac. Surg.
48:945-952[Medline].
|
| 31.
|
Woo, P. C. Y.,
H.-W. Tsoi,
L.-P. Wong,
H. C. H. Leung, and K.-Y. Yuen.
1999.
Antibiotics modulate vaccine-induced humoral immune response.
Clin. Diagn. Lab. Immunol.
6:832-837[Abstract/Free Full Text].
|
| 32.
|
Woo, P. C. Y.,
L. W. C. Chow,
E. S. K. Ma, and K. Y. Yuen.
1999.
Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model.
Pharmacol. Res.
39:49-54[CrossRef][Medline].
|
| 33.
|
Woo, P. C. Y.,
W. F. Ng,
H. C. H. Leung,
H. W. Tsoi, and K. Y. Yuen.
2000.
Clarithromycin attenuates cyclophosphamide-induced mucositis in mice.
Pharmacol. Res.
41:527-532[CrossRef][Medline].
|
| 34.
|
Yamauchi, H.,
E. Kobayashi,
T. Yoshida,
H. Kiyozaki,
Y. Hozumi,
R. Kohiyama,
Y. Suminaga,
I. Sakurabayashi,
A. Fujimura, and M. Miyata.
1998.
Changes in immune-endocrine response after surgery.
Cytokine
10:549-554[CrossRef][Medline].
|
| 35.
|
Yatsunami, J.,
N. Turuta,
K. Wakamatsu,
N. Hara, and S. Hayashi.
1997.
Clarithromycin is a potent inhibitor of tumor-induced angiogenesis.
Res. Exp. Med.
197:189-197[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, November 2000, p. 925-931, Vol. 7, No. 6
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Amsden, G. W.
(2005). Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother
55: 10-21
[Abstract]
[Full Text]
-
Woo, P. C. Y., To, A. P. C., Tse, H., Lau, S. K. P., Yuen, K.-y.
(2003). Clinical and Molecular Epidemiology of Erythromycin-Resistant Beta-Hemolytic Lancefield Group G Streptococci Causing Bacteremia. J. Clin. Microbiol.
41: 5188-5191
[Abstract]
[Full Text]